Trials / Recruiting
RecruitingNCT06860971
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
A Randomized, Double-Blind, Multicenter Phase III Clinical Trial Evaluating AL2846 Capsule Versus Placebo in Patients With Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma Who Failed Prior VEGFR-Targeted Therapy
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to demonstrate that, in subjects with locally advanced or metastatic iodine - refractory differentiated thyroid cancer who have failed previous VEGFR - targeted therapy, AL2846 can significantly prolong progression - free survival (PFS) compared with placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AL2846 Capsules | AL2846 Capsule is a multi - target tyrosine kinase inhibitor, which has significant inhibitory effects on c-Mesenchymal-epithelial transition factor (c - MET), stem cell factor receptor (c - KIT), VEGFR1 and Ret Proto-Oncogene (RET). |
| DRUG | AL2846 Placebo | AL2846 Placebo without drug substance. |
Timeline
- Start date
- 2025-04-18
- Primary completion
- 2027-01-01
- Completion
- 2028-01-01
- First posted
- 2025-03-06
- Last updated
- 2025-12-31
Locations
35 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06860971. Inclusion in this directory is not an endorsement.